In vitro activity of nicotinamide/antileishmanial drug combinations

Parasitology International

Volumn 60, Issue 1, 2011, Pages 19-24

  Gazanion, Elodie ^a   Vergnes, Baptiste ^a   Seveno, Marie ^a   Garcia, Deborah ^a   Oury, Bruno ^a   Ait Oudhia, Khatima ^c   Ouaissi, Ali ^b   Sereno, Denis ^a  

^a INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^b INSERM   (France)

^c HIGHER NATIONAL VETERINARY SCHOOL   (Algeria)

Author keywords

Antimonials; Drug combinations; Leishmania; Nicotinamide

Indexed keywords

AMPHOTERICIN B; ANTILEISHMANIAL AGENT; ANTIMONY; NICOTINAMIDE;

AMASTIGOTE; ARTICLE; CHEMOTHERAPY; DRUG RESISTANCE; DRUG TREATMENT FAILURE; IN VITRO STUDY; LEISHMANIA BRAZILIENSIS; LEISHMANIA INFANTUM; LEISHMANIA MEXICANA; LEISHMANIASIS; NONHUMAN; PRIORITY JOURNAL;

LEISHMANIA AMAZONENSIS; LEISHMANIA BRAZILIENSIS; LEISHMANIA INFANTUM;

EID: 78751580357     PISSN: 13835769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parint.2010.09.005     Document Type: Article

References (34)

1. Gradoni L., Soteriadou K., Louzir H., Dakkak A., Toz S.O., Jaffe C., et al. Drug regimens for visceral leishmaniasis in Mediterranean countries. Trop Med Int Health 2008, 13(10):1272-1276.
2. Sundar S., Rai M. Advances in the treatment of leishmaniasis. Curr Opin Infect Dis 2002, 15(6):593-598.
3. Croft S.L., Sundar S., Fairlamb A.H. Drug resistance in leishmaniasis. Clin Microbiol Rev 2006, 19(1):111-126.
4. Nieto J., Alvar J., Mullen A.B., Carter K.C., Rodríguez C., San Andrés M.I., et al. Pharmacokinetics, toxicities, and efficacies of sodium stibogluconate formulations after intravenous administration in animals. Antimicrob Agents Chemother 2003, 47(9):2781-2787.
5. Faraut-Gambarelli F., Piarroux R., Deniau M., Giusiano B., Marty P., Michel G., et al. In vitro and in vivo resistance of Leishmania infantum to meglumine antimoniate: a study of 37 strains collected from patients with visceral leishmaniasis. Antimicrob Agents Chemother 1997, 41(4):827-830.
6. Rojas R., Valderrama L., Valderrama M., Varona M.X., Ouellette M., Saravia N.G. Resistance to antimony and treatment failure in human Leishmania (Viannia) infection. J Infect Dis 2006, 193(10):1375-1383.
7. Lira R., Sundar S., Makharia A., Kenney R., Gam A., Saraiva E., et al. Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani. J Infect Dis 1999, 180(2):564-567.
8. Sundar S., Chatterjee M. Visceral leishmaniasis - current therapeutic modalities. Indian J Med Res 2006, 123(3):345-352.
9. Sereno D., Alegre A.M., Silvestre R., Vergnes B., Ouaissi A. In vitro antileishmanial activity of nicotinamide. Antimicrob Agents Chemother 2005, 49(2):808-812.
10. Al-Mulla Hummadi Y., Najim R., Al-Bashir N. Leishmania major and Leishmania tropica: I the in vitro effects of an immunomodulator, S2-Complex. Exp Parasitol 2005, 111(1):47-54.
11. Prusty D., Mehra P., Srivastava S., Shivange A.V., Gupta A., Roy N., et al. Nicotinamide inhibits Plasmodium falciparum Sir2 activity in vitro and parasite growth. FEMS Microbiol Lett 2008, 282(2):266-272.
12. Knip M., Douek I.F., Moore W.P., Gillmor H.A., McLean A.E., Bingley P.J., et al. Safety of high-dose nicotinamide: a review. Diabetologia 2000, 43(11):1337-1345.
13. Sereno D., Lemesre J.L. Axenically cultured amastigote forms as an in vitro model for investigation of antileishmanial agents. Antimicrob Agents Chemother 1997, 41(5):972-976.
14. Brun R., Schonenberger M. Cultivation and in vitro cloning of procyclic culture forms of Trypanosoma brucei in a semi-defined medium. Acta Trop 1979, 36(3):289-292.
15. Vergnes B., Sereno D., Tavares J., Cordeiro-da-Silva A., Vanhille L., Madjidian-Sereno N., et al. Targeted disruption of cytosolic SIR2 deacetylase discloses its essential role in Leishmania survival and proliferation. Gene 2005, 363:85-96.
16. Alzate J.F., Arias A.A., Moreno-Mateos D., Alvarez-Barrientos A., Jiménez-Ruiz A. Mitochondrial superoxide mediates heat-induced apoptotic-like death in Leishmania infantum. Mol Biochem Parasitol 2007, 152(2):192-202.
17. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984, 22:27-55.
18. Sereno D., Roy G., Lemesre J.L., Papadopoulou B., Ouellette M. DNA transformation of Leishmania infantum axenic amastigotes and their use in drug screening. Antimicrob Agents Chemother 2001, 45(4):1168-1173.
19. Shaha C. Apoptosis in Leishmania species & its relevance to disease pathogenesis. Indian J Med Res 2006, 123(3):233-244.
20. Chong Z.Z., Lin S.H., Maiese K. The NAD+ precursor nicotinamide governs neuronal survival during oxidative stress through protein kinase B coupled to FOXO3a and mitochondrial membrane potential. J Cereb Blood Flow Metab 2004, 24(7):728-743.
21. Crowley C.L., Payne C.M., Bernstein H., Bernstein C., Roe D. The NAD+precursors, nicotinic acid and nicotinamide protect cells against apoptosis induced by a multiple stress inducer, deoxycholate. Cell Death Differ 2000, 7(3):314-326.
22. Jha T.K. Drug unresponsiveness & combination therapy for kala-azar. Indian J Med Res 2006, 123(3):389-398.
23. Bryceson A. A policy for leishmaniasis with respect to the prevention and control of drug resistance. Trop Med Int Health 2001, 6(11):928-934.
24. Cerf B.J., Jones T.C., Badaro R., Sampaio D., Teixeira R., Johnson W.D. Malnutrition as a risk factor for severe visceral leishmaniasis. J Infect Dis 1987, 156(6):1030-1033.
25. Maciel B.L., Lacerda H.G., Queiroz J.W., Galvão J., Pontes N.N., Dimenstein R., et al. Association of nutritional status with the response to infection with Leishmania chagasi. Am J Trop Med Hyg 2008, 79(4):591-598.
26. Ouellette M., Drummelsmith J., Leprohon P., El Fadili K., Foucher A., Vergnes B., et al. Drug Resistance in Leishmania. Leishmania: After The Genome 2007, Horizon Press, Norwich, UK. P.J. Myler, N. Fasel (Eds.).
27. Vergnes B., Gourbal B., Girard I., Sundar S., Drummelsmith J., Ouellette M. A proteomics screen implicates HSP83 and a small kinetoplastid calpain-related protein in drug resistance in Leishmania donovani clinical field isolates by modulating drug-induced programmed cell death. Mol Cell Proteomics 2007, 6(1):88-101.
28. Bitterman K.J., Anderson R.M., Cohen H.Y., Latorre-Esteves M., Sinclair D.A. Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1. J Biol Chem 2002, 277(47):45099-45107.
29. Revollo J.R., Grimm A.A., Imai S. The regulation of nicotinamide adenine dinucleotide biosynthesis by Nampt/PBEF/visfatin in mammals. Curr Opin Gastroenterol 2007, 23(2):164-170.
30. Horsman M.R., Høyer M., Honess D.J., Dennis I.F., Overgaard J. Nicotinamide pharmacokinetics in humans and mice: a comparative assessment and the implications for radiotherapy. Radiother Oncol 1993, 27(2):131-139.
31. Bernier J., Stratford M.R., Denekamp J., Dennis M.F., Bieri S., Hagen F., et al. Pharmacokinetics of nicotinamide in cancer patients treated with accelerated radiotherapy: the experience of the Co-operative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer. Radiother Oncol 1998, 48(2):123-133.
32. Seifert K., Escobar P., Croft S.L. In vitro activity of anti-leishmanial drugs against Leishmania donovani is host cell dependent. J Antimicrob Chemother 2010, 65(3):508-511.
33. Osar Z., Samanci T., Demirel G.Y., Damci T., Ilkova H. Nicotinamide effects oxidative burst activity of neutrophils in patients with poorly controlled type 2 diabetes mellitus. Exp Diabesity Res 2004, 5(2):155-162.
34. Ungerstedt J.S., Blömback M., Söderström T. Nicotinamide is a potent inhibitor of proinflammatory cytokines. Clin Exp Immunol 2003, 131(1):48-52.